Cue Biopharma, Inc. (CUE) Stock
CUE Key Statistics
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
CEO: Lucinda Warren. Company website
CUE — Frequently Asked Questions
What is the CUE stock price today?
Cue Biopharma, Inc. (CUE) trades at $27.66, up 23.87% on the day, as of Nov 12, 2026 09:48 UTC.
What is Cue Biopharma, Inc.'s market cap?
Cue Biopharma, Inc. has a market capitalisation of $2.18B, calculated from the live CUE share price and shares outstanding.
What is the P/E ratio of CUE?
CUE has no meaningful price-to-earnings ratio: Cue Biopharma, Inc. lost $0.32 per share over the last twelve months, and a P/E is only defined on positive earnings.
How much revenue does Cue Biopharma, Inc. make?
Cue Biopharma, Inc. generated revenue of $27.47M over the trailing twelve months, which puts the stock at 79.39 times sales.
What is the 52-week range for CUE?
CUE has traded between $0.26 and $45.50 over the past 52 weeks, and the last price is 39.2% below that high.
Is Cue Biopharma, Inc. profitable?
No. Cue Biopharma, Inc. is loss-making, with a net margin of -96.85% over the trailing twelve months.
What is the analyst price target for CUE?
Wall Street analysts rate CUE Buy, with an average price target of $4.33, 84.3% below the current price.
What sector is Cue Biopharma, Inc. in?
Cue Biopharma, Inc. is classified under the Healthcare sector and the Biotechnology industry, and is domiciled in US .
Who is the CEO of Cue Biopharma, Inc.?
Lucinda Warren is the chief executive of Cue Biopharma, Inc., which employs 41 people.
Where can I track CUE in real time?
QFI Terminal shows CUE with live charts, full financials, the options chain with gamma exposure, institutional ownership and analyst ratings on one screen. The free plan has no time limit and asks for no card.
See CUE live in QFI Terminal
Interactive charts, full financials, options chain, gamma exposure, ownership and analyst ratings, all in one institutional-grade terminal.
Open CUE in Terminal See plans